Sodium Deposition in Soft Tissues of Patients With Kidney Disease

Study Lead

Dr. Christopher McIntyre

London Health Sciences Centre


Kidneys have a key role in sodium hemostasis through their excretory function. In patients with chronic kidney disease (CKD), kidney function is impaired; thus, suggesting that sodium handling is abnormal in this setting with long-term sodium loading (from oral intake) and lack of adequate urinary excretion. Yet, sodium concentration needs to stay relatively constant to prevent fatal intra-cellular accumulation, which would result in cell injury and death. In hemodialysis patients, at least a part of this extra sodium is non-osmotically active and deposited in the skin, muscle, and skeleton.

Furthermore, it has become increasingly recognized that sodium (once accumulated in tissues) is directly pro-inflammatory, affecting the innate immune system by regulating the activity of macrophages in skin. This linkage between sodium and inflammation indicates a potential link between sodium deposition and uremic symptoms experienced by patients.

There have been no studies to date examining the sodium deposition in the skin, muscle, and skeleton of patients with different kidney function and renal replacement therapy.

This is a pilot study involving a single center recruiting patients from the prevalent maintenance hemodialysis, peritoneal dialysis , CKD stage 1-5, and heart failure populations of London, Ontario, compared to healthy controls. Once recruited, participants will undergo one study visit with the potential of up to two follow-up visits (on a non-dialysis day for hemodialysis patients). Participants will be followed for up to two years after the first study visit. Each session will include symptom questionnaires, the five times sit to stand and 60-second chair stand test (excluding all children), blood pressure and heart rate measurements, blood work (excluding healthy children and adolescents), urine sampling (excluding those on dialysis), an echocardiogram (excluding healthy controls), and an MRI scan of the lower leg detecting sodium content.


Inclusion Criteria:

  • Age greater than or equal to 6 years
  • For patients on maintenance hemodialysis or peritoneal dialysis: more than 3 months duration of therapy
  • For patients with CKD stage 1-5: CKD stage 1-5 and no indications to start dialysis
  • For heart failure patients: with or without renal dysfunction
  • For healthy controls: lack of kidney disease, heart failure, liver cirrhosis, and peripheral edema

For subsequent visits (must meet 1 of the below indicators):

  • Change in dialysis prescription
  • Change in renal replacement therapy modality
  • Change in medication
  • Parathyroidectomy
  • Intervention added to or removed from dialysis (i.e. such as but not limited exercise, cooling, and ischemic preconditioning)

Exclusion Criteria:

  • Pregnant, breastfeeding or intending pregnancy
  • Unable to give consent or understand written information
  • Contraindication to MRI study

Type of Participation

Clinical Trial


Chronic Kidney Disease


Hemodialysis, Peritoneal Dialysis





Related studies

  • Mind the Gap

    Overview: Identifying and implementing individualized, accessible, and culturally sensitive solutions to address mental health care in individuals receiving hemodialysis

    Study type: Patient Partnership, Survey

    February 2, 2024

  • Home First: A pragmatic provincial clinical demonstration project in advanced Chronic Kidney Disease

    Overview: The goal of this program is to offer all patients with advanced CKD in the Manitoba Renal Program enhanced dialysis education and support from a patient navigator.

    Study type: Patient Partnership

    January 25, 2024

  • Multispectral Colour Sensing Point-of-Care Testing Device for CKD Monitoring

    Overview: Developing a point-of-care device that uses advanced colour sensors to measure creatinine levels in the urine to improve Chronic Kidney Disease monitoring.

    Study type: Interview

    January 24, 2024